Insulin aspart, recombinant Subcutaneous and Relafen DS
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Relafen DS and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: nabumetone
Brand name: Relafen DS, Relafen
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Relagesic
- Insulin aspart, recombinant Subcutaneous-Relamine
- Insulin aspart, recombinant Subcutaneous-Relasin-HC
- Insulin aspart, recombinant Subcutaneous-Relcof C
- Insulin aspart, recombinant Subcutaneous-Relcof DM
- Insulin aspart, recombinant Subcutaneous-Releevia
- Relafen DS-Insulin degludec
- Relafen DS-Insulin Degludec (U-100) Prefilled Pens
- Relafen DS-Insulin Degludec (U-100) Vials
- Relafen DS-Insulin Degludec (U-200) Prefilled Pens
- Relafen DS-Insulin degludec and liraglutide
- Relafen DS-Insulin degludec and liraglutide Subcutaneous